Narratives

What's New

Your Valuation

Global Community

Our community narratives are driven by numbers and valuation.

Author Program NEW

Global Weekly Picks

Optimi Health

Lou_Basenese

Community Contributor

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.

View narrative

US$11

57.5% undervalued

2.9k

Novo Nordisk

WealthAP

Community Contributor

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.

View narrative

DKK 407.77

20.1% undervalued

10.00%

Revenue growth p.a.

6.2k

Zoetis

ValueInvestingSubstack

Community Contributor

Zoetis down -50% over the past year

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.

View narrative

US$92.92

18.9% undervalued

4.06%

Revenue growth p.a.

1.9k

Centrus Energy

CentryResearch

Community Contributor

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Nuclear power is back in the spotlight as data centers and AI push demand for reliable electricity, but a lesser-known fuel shortage could slow down the next wave of new reactors. One U.S. supplier sits close to this choke point, while many reactor builders may be forced to wait until the fuel supply catches up.

View narrative

US$190

13.7% undervalued

24.82%

Revenue growth p.a.

2.9k

Netcall

⚡ Two-Minute Drill: Netcall PLC - This £200M AI Stock Is Already Running the NHS

A little-known UK software firm is already helping hospitals, councils, and banks automate everyday tasks using AI, yet the market still treats it like ordinary workflow software. See why its deep roots in public services could drive years of growth—and how big tech rivals could spoil the story.Read more

UK£2.17

45.6% undervalued

European_Hidden_Gem_Stocks's

Fair Value

Revenue

23.47% p.a.

Profit Margin

4.67%

Future PE

83.88x

Price in 2031

UK£3.4

PayPal Holdings

The Underrated Transformation of a Digital Payments Giant

The Underrated Transformation of a Digital Payments Giant I have been invested in PayPal for several years and have consciously decided to increase my position further. The reason is not short-term speculation, but rather my conviction that the market is currently underestimating the company’s long-term development and potential.Read more

US$90.31

37.8% undervalued

WisetoWealth's

Fair Value

Revenue

10% p.a.

Profit Margin

15%

Future PE

9.79x

Price in 2031

US$129.99

LVMH Moët Hennessy - Louis Vuitton Société Européenne

The Luxury Titan Mispriced by a Short‑Sighted Market

LVMH faces a demand slowdown, but the business keeps growing as it adds brands, expands its hotel footprint, and leans into high-end categories. If the market is judging the company on the recent dip while it keeps building for the long run, this could be a rare moment when a luxury leader looks undervalued.Read more

€680

31.4% undervalued

JH7's

Fair Value

Revenue

17.11% p.a.

Profit Margin

13.46%

Future PE

21.07x

Price in 2031

€1.02k

Rezolve AI

⚡ Two-Minute Drill: Rezolve AI - The AI That Doesn't Recommend Products. It Buys Them.

Rezolve AI wants to turn shopping chats into completed purchases, handling everything from questions to checkout in one conversation. The upside is big if retailers adopt this approach quickly—but it hinges on execution and whether giants like Amazon or Shopify decide to build their own version.Read more

US$80.78

97.2% undervalued

European_Hidden_Gem_Stocks's

Fair Value

Profit Margin

19%

Future PE

21.08x

Price in 2031

US$128.27

Terra Balcanica Resources

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Dundee paid C$1.3B for a mine in Bosnia. The explorer 80 km away in the same belt is worth C$4M.Read more

CA$0.4

87.5% undervalued

Blagget's

Fair Value

Terra Balcanica is a pre-revenue explorer, so revenue/earnings forecasting doesn't apply. My fair value is based on relative valuation(to mention a few, I will add more to this later on when I got some time to write) : • Dundee paid C$1.3B for a mine in Bosnia, ~80 km away in the same belt. • Military Metals still trades at ~C$14M after losing its flagship Trojarová licence (75–85% of its value) 4x TERA's ~C$4M cap. • Catalyst: China's antimony export ban pause ends in November 2026; antimony sits on NATO, EU, and US critical-metals lists. Fair value = assumed re-rated market cap ÷ shares outstanding. This is a speculative, pre-resource situation, the valuation reflects asymmetric risk/reward, not cash flow.

Charter Communications

Charter is undervalued - Here's why.

CHTR closed Q-2 with 119mm shares. At the current price of $124 per share, that translates to a mkt.Read more

US$87.07

41.6% overvalued

david_6nroa's

Fair Value

Revenue

-2.44% p.a.

Profit Margin

9.05%

Future PE

2.99x

Price in 2031

US$156.65

Saudi Ground Services

Saudi Ground Services revenue will rise by nearly 40%

Saudi Ground Services goes from near-monopoly to a more open market, and the share price already reflects a lot of fear about new rivals. The key question is whether its long-standing airline contracts and cash-rich, low-investment business can keep dividends and profits steady as competition ramps up.Read more

ر.س45

37.6% undervalued

Valtersa's

Fair Value

Revenue

39.89% p.a.

Profit Margin

13.46%

Future PE

14.22x

Price in 2029

ر.س76.1

Kuros Biosciences

How a Mispriced Medtech Engine is Disrupting $5,000 Bone Graft Giants.

Many investors treat Kuros Biosciences like a risky drug developer, but the company now makes a bone-graft product that aims to help hospitals get similar patient results while spending less. The story hinges on surgery centers shifting toward lower-cost care, Kuros’s control over its key technology, and a few practical risks that could slow adoption.Read more

US$342.18

92.5% undervalued

AnimalDoctorKwon's

Fair Value

Revenue

62% p.a.

Profit Margin

50%

Future PE

20x

Price in 2031

US$478.36

Kartoon Studios

Kartoon Studios just Banked $39.2 Million.. So, Why is TOON Still Trading Below Cash?

Kartoon Studios collects a big legal payout and suddenly sits on a pile of cash, yet the stock still trades as if that money might not stick. The real question is whether the company can stop burning cash and turn its well-known characters into steady deals before that cushion fades.Read more

US$0.48

20.8% overvalued

DaneDruss's

Fair Value

I use a conservative cash-runway approach because Kartoon Studios does not yet have reliable positive earnings to support a P/E valuation. The company reported more than $40 million in cash and no debt as of June 30, 2026. I deduct approximately $11.7 million, representing one year of operating cash use annualized from Q1 2026, then divide the remaining $28.3 million by approximately 59.1 million basic shares. This produces a fair-value anchor of about $0.48 per share. This is not a liquidation value or earnings forecast. It assigns no value to unreceived settlement proceeds, warrant proceeds, retained intellectual property, or execution upside, while potential dilution remains a material risk. The estimate should be revised when the next quarterly filing verifies cash, liabilities, operating burn, and share count.